Hyphens inks MOU with A*Star's A*ccelerate
The five-year commercialisation deal covers development of products targeting eczema, acne, pigmentary disorders
Singapore
SGX Catalist-listed Hyphens Pharma International Limited signed a Memorendum of Understanding (MOU) with A*Star's commercial arm A*ccelerate, previously known as Exploit Technologies, at the opening ceremony of its corporate headquarters and integrated facility in Singapore on Wednesday.
Lim See Wah, Hyphen Pharma's chairman and CEO, said: "Our new corporate headquarters and integrated facility will not only provide enhanced efficiency and productivity, it will also serve as an oasis for our people to germinate creative and innovative ideas."
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
S&P slashes Boeing credit outlook as rating hovers above junk status
Honda to spend US$11 billion on EV strategy in Canada
GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology
Mapletree Industrial Trust Q4 DPU rises 0.9% to S$0.0336
Nasdaq’s profit falls as shaky economy keeps IPO revival elusive
iFast Q1 net profit surges on ePension unit performance